RSV Vaccines for the World

14-16 October 2013, Tiara Park Atlantico Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Day One

Final Conference Programme | Monday 14th October

07.30 onwards
Registration

SESSION 1:
OPENING PLENARY SESSION

Moderator: Gregory Glenn (Novavax Inc., Rockville, Maryland, USA)

09.00-09.10
RSVVW 2013 Conference Welcome & Introduction
Gregory Glenn (Novavax Inc., Rockville, Maryland, USA) and Deborah Higgins (PATH, Seattle, Washington, USA)

09.10-09.40
‘RSV Vaccines: The Road Ahead’
Ruth A. Karron (The Johns Hopkins University, Baltimore, Maryland, USA)

09.40-09.50
‘Gates Foundation strategy for RSV’
Keith Klugman (Gates Foundation, Seattle, Washington, USA)

09.50-10.20
‘Immunogenicity of RSV subunit vaccine candidates: An historical perspective’
Jean-Francois X. Toussaint (GSK Biologicals, Rixensart, Belgium)

10.20-10-50
‘RSV vaccines: An unhappy past, but a hopeful future?’
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)

10.50-11.20
Coffee Break & Poster Set-Up

SESSION 2:
RSV VACCINES IN CLINICAL DEVELOPMENT: SAFETY, IMMUNOGENICITY AND PATH FORWARD

Moderator: Deborah Higgins (PATH, Seattle, Washington, USA)

11.20-11.45
‘Clinical experience with live-attenuated RSV vaccines’
Peter Collins (NIAID/NIH, Bethesda, Maryland, USA)

11.45-12.10
‘Lessons for RSV from influenza and polio- diseases for which there are options of live, mucosally delivered and inactivated vaccine approaches’
Peter Wright (Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA)

12.10-12.35
‘Clinical experience with the RSV F nanoparticle vaccine’
Gregory Glenn (Novavax Inc, Rockville, Maryland, USA)

12.35-13.00
‘A novel genetic vaccine to prevent RSV infection’
Elisa Scarselli (Okairos Srl, Rome, Italy)

13.00-14.00
Lunch Break & Posters

SESSION 3:
RSV ANTIGENS

Moderator: Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)

14.00-14.25
‘Atomic structure of pre- and post-fusion RSV F’
Jason S. McLellan (NIAID/NIH, Bethesda, Maryland, USA)

14.25-14.50
‘Structural vaccinology: is a pre-fusion RSV F antigen superior to post-fusion F’
Kurt A. Swanson, Ethan C. Settembre, Christine A. Shaw, Philip R. Dormitzer and Andrea Carfi (Novartis Vaccines, Cambridge, Massachusetts, USA)

14.50-15.15
‘Immunogenicity of a structure-based computationally designed RSV fusion protein subunit vaccine’
James Crowe (Vanderbilt University, Nashville, Tennessee, USA)

15.15-15.35
‘A novel RSV F antigen designed to adopt PreF conformation: Immunogenicity, efficacy and safely in rodent models of RSV infection’
Ann-Muriel Steff, Jean-Francois Toussaint, Normans Blais and Denis Martin (GlaxoSmithKline Vaccines, Laval, Canada)

15.35-15.55
‘Options for using pre-fusion RSV F as a vaccine antigen’
Barney S. Graham (NIH, Bethesda, Maryland, USA)

15.55-16.15
Tea Break & Posters

SESSION 4:
CLINICAL STRATEGIES TO ADDRESS THE BURDEN OF RSV DISEASE – PART I

Moderator: Pedro A. Piedra (Baylor College of Medicine, Houston, Texas, USA)

16.15-16.40
‘Prevention of RSV in infants: Maternal immunization as a potential strategy’
Janet Englund (Seattle Children’s Hospital, Seattle, Washington, USA)

16.40-17.05
‘Maternal immunization for RSV - The promise and the challenge’
Deborah Higgins (PATH, Seattle, Washington, USA)

17.05-17.30
‘Defining the duration of protective maternal RSV antibodies in infants’
James Nokes (KEMRI-WT, Kilifi, Kenya/Warwick University, Coventry, UK)

17.30-17.50
‘Ethical, Social and cultural considerations in planning and conducting maternal immunization trials for RSV vaccines’
Billie-Jo Hardy (University Health Network, Toronto, Ontario, Canada)

17.50-18.10
‘Transfer and decay of Respiratory Syncytial Virus antibody levels in mother-infant pairs in Bangladesh’
Helen Y. Chu, Mark C. Steinhoff, Gretchen Langdon, K. Zaman, Eliza Roy, Mary Ann Formica, Edward Walsh and Janet A. Englund (University of Washington, Seattle, Washington, USA)

18.10-18.30
‘Long-term airway morbidity: A previously unrecognized health benefit of future RSV vaccines’
Louis Bont, Maarten O. Blanken, Maroeska M. Rovers, Jorine M. Molenaar, Pauline L. Winkler-Seinstra, Adam Meijer and Jan L.L. Kimpen (University Medical Center Utrecht, Utrecht, The Netherlands)

18.30
RSVVW 2013 Welcome & Poster Session

 

RSVVW 2013 Sponsors

  • ADMA Biologics
  • NatureGeneTherapy.com
  • Retroscreen Virology
  • Immunovaccine
  • Sanofi Pasteur
  • Aldevron
  • NanoBio
  • PATH
  • Crucell
  • Aldevron
  • Pevion Vaccines
  • Novartis Vaccines
  • VLP Biotech
  • Okairos
  • Mucosis
  • Inovio Pharmaceuticals
  • Mymetics
  • Ablynx
  • Novavax

RSVVW 2013 Downloads

RSVVW 2013 Leaflet

RSVVW 2013 Mailing List

Name
E-mail Address
What is 1+4-2?